Press "Enter" to skip to content

FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment – Nasdaq

admin 0

FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment  Nasdaq

F. Hoffmann-La Roche Ltd/ FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual.

“breast cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *